Trillium Asset Management’s GSK GSK Stock Holding History

Trillium Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-8,870	Closed	-$420K	–	236
2020 Q1	$420K	Buy	8,870 +16	+0.2%	+$853	0.02%	201
2019 Q4	$520K	Sell	8,854 -347	-4%	-$19.3K	0.02%	206
2019 Q3	$491K	Sell	9,201 -14	-0.2%	-$720	0.02%	212
2019 Q2	$461K	Buy	9,215 +201	+2%	+$10.1K	0.02%	199
2019 Q1	$471K	Buy	9,014 +564	+7%	+$28.2K	0.02%	206
2018 Q4	$403K	Sell	8,450 -40	-0.5%	-$1.97K	0.02%	204
2018 Q3	$427K	Sell	8,490 -61	-0.7%	-$3.1K	0.02%	209
2018 Q2	$431K	Sell	8,551 -57	-0.7%	-$2.87K	0.02%	203
2018 Q1	$420K	Buy	8,608 +1,538	+22%	+$71.6K	0.02%	204
2017 Q4	$314K	Sell	7,070 -53,012	-88%	-$2.45M	0.02%	206
2017 Q3	$3.05M	Buy	60,082 +2,032	+4%	+$103K	0.17%	135
2017 Q2	$3.13M	Buy	58,050 +2,160	+4%	+$115K	0.19%	133
2017 Q1	$2.94M	Buy	55,890 +2,256	+4%	+$114K	0.19%	131
2016 Q4	$2.58M	Sell	53,634 -2,756	-5%	-$136K	0.17%	133
2016 Q3	$3.04M	Buy	56,390 +48,580	+622%	+$2.66M	0.2%	126
2016 Q2	$423K	Sell	7,810 -372	-5%	-$19.6K	0.03%	193
2016 Q1	$415K	Sell	8,182 -255	-3%	-$12.7K	0.03%	182
2015 Q4	$426K	Sell	8,437 -689	-8%	-$35.1K	0.03%	187
2015 Q3	$438K	Buy	9,126 +89	+1%	+$4.63K	0.03%	186
2015 Q2	$471K	Sell	9,037 -109	-1%	-$6.14K	0.03%	184
2015 Q1	$528K	Sell	9,146 -868	-9%	-$49.8K	0.03%	178
2014 Q4	$535K	Sell	10,014 -1,967	-16%	-$110K	0.04%	176
2014 Q3	$689K	Sell	11,981 -77,248	-87%	-$4.74M	0.06%	156
2014 Q2	$5.96M	Buy	89,229 +4,239	+5%	+$287K	0.51%	82
2014 Q1	$5.68M	Buy	84,990 +5,584	+7%	+$378K	0.53%	74
2013 Q4	$5.3M	Buy	79,406 +834	+1%	+$54.1K	0.52%	87
2013 Q3	$4.93M	Sell	78,572 -58,034	-42%	-$3.74M	0.55%	81
2013 Q2	$8.53M	Buy	+136,606	New	+$8.67M	1.05%	34

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Trillium Asset Management's GSK Position: Q2 2020 in Review

Trillium Asset Management sold out of GSK (GSK) in Q2 2020, closing a stake of 8,870 shares — an estimated $420K sold.

Trillium Asset Management first reported a position in GSK in Q2 2013 and held it in 28 quarters. The position peaked at $8.53M in Q2 2013. 841 funds tracked by Wall St. Rank hold GSK as of Q2 2020.

Trillium Asset Management reported no remaining GSK position as of Q2 2020 after selling out during the quarter.
Trillium Asset Management sold 8,870 GSK shares in Q2 2020, an estimated $420K.
Trillium Asset Management first reported a position in GSK in Q2 2013 and held it in 28 quarters.
Trillium Asset Management's GSK position peaked at $8.53M in Q2 2013.
841 funds tracked by Wall St. Rank held GSK as of Q2 2020.

Based on Trillium Asset Management's 13F filing for Q2 2020, filed 6 Aug 2020.